Published in Blood on November 24, 2010
LTFU for Gene Transfer Subjects With Hemophilia B | NCT00515710
In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature (2011) 4.81
A largely random AAV integration profile after LPLD gene therapy. Nat Med (2013) 2.42
Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood (2013) 2.09
Gene therapy returns to centre stage. Nature (2015) 1.95
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest (2015) 1.46
Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci U S A (2012) 1.31
Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma? Hum Gene Ther (2015) 1.25
Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. Mol Ther (2012) 1.19
The gene therapy journey for hemophilia: are we there yet? Blood (2012) 1.10
Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side-Effects. Mol Ther Methods Clin Dev (2014) 1.08
Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis. Ann Neurol (2012) 1.05
Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther (2012) 0.98
Adeno-associated Vector Toxicity-To Be or Not to Be? Mol Ther (2015) 0.98
Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs. Hum Gene Ther Clin Dev (2015) 0.95
Developments in Viral Vector-Based Vaccines. Vaccines (Basel) (2014) 0.94
Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates. Mol Ther (2014) 0.90
Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia. J Genet Syndr Gene Ther (2012) 0.90
AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior. Hum Gene Ther (2012) 0.89
Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon. F1000 Med Rep (2011) 0.88
Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction. Hum Gene Ther (2013) 0.88
AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity. PLoS Pathog (2015) 0.87
Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges. Expert Rev Hematol (2011) 0.87
Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice. Gene Ther (2013) 0.86
Telomerase gene therapy: a novel approach to combat aging. EMBO Mol Med (2012) 0.82
rAAV-mediated tumorigenesis: still unresolved after an AAV assault. Mol Ther (2012) 0.81
GeIST: a pipeline for mapping integrated DNA elements. Bioinformatics (2015) 0.80
Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients. Mol Ther (2016) 0.80
Pseudotyped AAV vector-mediated gene transfer in a human fetal trachea xenograft model: implications for in utero gene therapy for cystic fibrosis. PLoS One (2012) 0.79
AAV Gene Therapy for Liver Disease. Hum Gene Ther (2016) 0.79
Adeno-associated virus-mediated microRNA delivery and therapeutics. Semin Liver Dis (2015) 0.78
Quest for safety at AAValon. Blood (2011) 0.78
Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy. Mol Ther Methods Clin Dev (2014) 0.77
Somatic Therapy of a Mouse SMA Model with a U7 snRNA Gene Correcting SMN2 Splicing. Mol Ther (2016) 0.76
Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models. Hum Gene Ther (2017) 0.76
AAV Infection: Protection from Cancer. Hum Gene Ther (2016) 0.76
Genotoxicity in Mice Following AAV Gene Delivery: A Safety Concern for Human Gene Therapy? Mol Ther (2016) 0.76
Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease. Mol Ther (2016) 0.75
Local and systemic responses following intravitreous injection of AAV2-encoded modified Volvox channelrhodopsin-1 in a genetically blind rat model. Gene Ther (2015) 0.75
A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme. World J Exp Med (2011) 0.75
An episomal CRISPR/Cas9 system to derive vector-free gene modified mammalian cells. Protein Cell (2016) 0.75
Hitting the target without pulling the trigger. Mol Ther (2015) 0.75
Vector integration and tumorigenesis. Hum Gene Ther (2014) 0.75
Influence of immune responses in gene/stem cell therapies for muscular dystrophies. Biomed Res Int (2014) 0.75
Lessons Learned from Animal Models of Inherited Bleeding Disorders. Hematol Educ (2014) 0.75
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med (2008) 17.21
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
HIV-1 integration in the human genome favors active genes and local hotspots. Cell (2002) 12.60
In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science (1989) 10.87
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Genomic sequencing and methylation analysis by ligation mediated PCR. Science (1989) 7.38
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 7.05
DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res (2007) 6.89
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet (2000) 5.80
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 5.58
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med (2010) 4.76
HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res (2007) 4.72
Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther (1998) 3.77
AAV vector integration sites in mouse hepatocellular carcinoma. Science (2007) 3.73
Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol (2005) 3.51
Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol (2001) 3.38
Selection of target sites for mobile DNA integration in the human genome. PLoS Comput Biol (2006) 3.21
AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet (2003) 2.81
Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS One (2007) 2.48
Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol (1999) 2.37
Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet (2004) 2.27
Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc (2010) 2.24
Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med (2009) 2.19
Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther (2006) 2.15
Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol (2005) 2.09
Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood (2010) 2.05
Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther (2000) 2.04
Adeno-associated virus vector integration junctions. J Virol (1997) 2.03
Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood (2008) 1.98
Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood (1998) 1.96
Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol Ther (2003) 1.92
Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol (2005) 1.85
Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther (2001) 1.81
Integration target site selection by a resurrected human endogenous retrovirus. Genes Dev (2009) 1.62
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR J (2009) 1.43
Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood (1998) 1.40
Tumours of the liver. IARC Sci Publ (1994) 1.24
Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. Mol Ther (2005) 1.22
Methods for integration site distribution analyses in animal cell genomes. Methods (2008) 1.21
Role of intron I in expression of the human factor IX gene. J Biol Chem (1995) 1.15
Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. Blood (1997) 1.03
AAV vectors, insertional mutagenesis, and cancer. Mol Ther (2007) 1.03
Expression of NGF in hepatocellular carcinoma cells with its receptors in non-tumor cell components. Int J Cancer (2005) 0.90
Microarray analysis of gene expression of mouse hepatocytes of different ploidy. Mamm Genome (2007) 0.89
Production of nerve growth factor by mouse hepatocellular carcinoma cells and expression of TrkA in tumor-associated arteries in mice. Gastroenterology (2002) 0.87
Relationship of hepatocyte ploidy levels with body size and growth rate in mammals. Genome (2001) 0.83
QIIME allows analysis of high-throughput community sequencing data. Nat Methods (2010) 85.34
Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30
Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med (2008) 17.21
PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinformatics (2009) 15.93
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Short pyrosequencing reads suffice for accurate microbial community analysis. Nucleic Acids Res (2007) 9.15
Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell (2008) 8.41
Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol (2004) 8.27
Minimum information about a marker gene sequence (MIMARKS) and minimum information about any (x) sequence (MIxS) specifications. Nat Biotechnol (2011) 7.53
DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res (2007) 6.89
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71
The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis. PLoS Pathog (2008) 5.28
CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med (2007) 5.24
Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol (2010) 4.97
In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature (2011) 4.81
Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med (2011) 4.78
HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res (2007) 4.72
Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet (2011) 4.67
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood (2002) 4.60
Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog (2009) 4.24
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther (2009) 3.93
Bayesian community-wide culture-independent microbial source tracking. Nat Methods (2011) 3.88
Global landscape of HIV-human protein complexes. Nature (2011) 3.70
Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog (2006) 3.67
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood (2009) 3.65
Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2010) 3.54
Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest (2003) 3.52
Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol (2002) 3.46
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood (2002) 3.45
The human gut virome: inter-individual variation and dynamic response to diet. Genome Res (2011) 3.32
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther (2008) 3.28
Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther (2007) 3.26
Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature (2013) 3.21
Selection of target sites for mobile DNA integration in the human genome. PLoS Comput Biol (2006) 3.21
Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther (2011) 3.10
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med (2012) 2.87
HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog (2011) 2.68
DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucleic Acids Res (2008) 2.64
New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell (2008) 2.61
Disordered microbial communities in the upper respiratory tract of cigarette smokers. PLoS One (2010) 2.60
Rapid evolution of the human gut virome. Proc Natl Acad Sci U S A (2013) 2.53
Commensal bacteria-derived signals regulate basophil hematopoiesis and allergic inflammation. Nat Med (2012) 2.49
Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS One (2007) 2.48
Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J Virol (2010) 2.45
Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol (2010) 2.43
Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther (2006) 2.33
Associating microbiome composition with environmental covariates using generalized UniFrac distances. Bioinformatics (2012) 2.19
Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice. J Clin Invest (2012) 2.18
Immune responses to AAV in clinical trials. Curr Gene Ther (2007) 2.13
The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood (2011) 2.11
Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol (2008) 2.10
Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood (2012) 2.10
Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood (2013) 2.09
The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog (2008) 2.06
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood (2007) 2.05
Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood (2010) 2.05
X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med (2009) 2.02
Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood (2008) 2.01
HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog (2011) 2.00
Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood (2008) 1.98